India Glycols Limited has informed the Exchange about Investor Presentation
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Glycols reported record quarterly performance in Q3 FY26 with net revenue of ₹1,102 Cr (up 13% YoY), EBITDA of ₹176 Cr (up 36.1%), and PAT of ₹68 Cr (up 18.9%). For 9M FY26, net revenue stood at ₹3,235 Cr (up 11.4%), EBITDA at ₹487 Cr (up 28.9%), and PAT at ₹206 Cr (up 23.4%). EBITDA margin expanded sharply by 277 bps to 16.0% in Q3, driven by strong performance in Bio-Fuel (revenue up 45.2%) and Bio-Based Specialties (EBIT margin up from 8.5% to 12.8%). The company reduced total debt by ₹582 Cr, of which ₹467 Cr was raised through a preferential allotment of 51 lakh shares at ₹915 each, with the balance from internal accruals. The presentation also outlined progress on the proposed demerger of the Spirits & Biofuel and Bio Pharma businesses into two separate listed entities, with an appointed date of April 1, 2026.
The strong Q3 results, expanding margins, and significant debt reduction are positive signals for shareholders, indicating improved profitability and a stronger balance sheet. The demerger into focused listed entities (IGL Spirits and Ennature Bio Pharma) could unlock value by allowing investors to independently value each business segment.